Ziovir-TLD is a Dolutegravir + Lamivudine + Tenofovir Disoproxil Fumarate, a combination medicine used to treat HIV infection. It helps control the virus, reduces the risk of complications, and improves immune function. This fixed-dose combination includes an integrase inhibitor (Dolutegravir) and two nucleoside reverse transcriptase inhibitors (Lamivudine and Tenofovir Disoproxil Fumarate), which work together to suppress viral replication. Regular use can lower the viral load and prevent HIV progression to AIDS.
How Ziovir-TLD Works?
Dolutegravir + Lamivudine + Tenofovir disoproxil fumarate is an anti-HIV composition. It acts by inhibiting the operation of the reverse transcriptase enzyme. This enzyme is responsible for the generation of HIV.
Dolutegravir: Dolutegravir is an integrase strand transfer inhibitor (INSTI) that stops the HIV replication cycle by blocking the HIV integrase enzyme, which is important for inserting viral DNA into the host cell's DNA. By inhibiting the "strand transfer" step in this integration process, dolutegravir prevents the virus from incorporating its genetic material into the host's genome, effectively stopping the virus from multiplying and producing new virus particles.
Lamivudine: Lamivudine's mechanism of action involves intracellular phosphorylation to its active triphosphate form, which then competitively inhibits viral DNA synthesis by competing with natural cytidine triphosphate for incorporation into the viral DNA by viral reverse transcriptase enzymes for HIV and HBV. Once incorporated into the viral DNA chain, the lack of a 3'-hydroxyl group prevents the formation of further phosphodiester bonds, thus terminating DNA elongation and preventing viral replication.
Tenofovir: Tenofovir works by acting as an acyclic nucleoside phosphonate that, once activated within the cell, inhibits viral reverse transcriptase (for HIV) and HBV polymerase (for hepatitis B). It achieves this by competing with the natural deoxyadenosine 5'-triphosphate (dATP) for incorporation into the viral DNA strand, and once incorporated, it causes premature chain termination and prevents viral replication.
HIV/ ARV Generic Manufacturer Company in India
Sunrise Remedies is an India-based pharmaceutical manufacturer that produces HIV/ARV medications, among other products. The company is ISO 9001:2015 certified and has a WHO-GMP certified manufacturing facility.
HIV/ARV products
Sunrise Remedies manufactures several antiretroviral (ARV) and anti-HIV products. A few examples include:
· Kabavir: Contains Abacavir Sulphate, a type of nucleoside reverse transcriptase inhibitor (NRTI).
· Ziovir: Contains Tenofovir Disoproxil Fumarate, which belongs to the class of medication known as nucleotide reverse transcriptase inhibitors (NRTIs).
· Ziovir-TLD: This is an anti-HIV medicine containing Tenofovir Disoproxil Fumarate, Lamivudine, and Dolutegravir.
· Lamirid: Contains Lamivudine, an NRTI used to prevent HIV from replicating.
· Ribaviz: Contains Ribavirin and is an antiviral medication used to treat certain viral infections.
Manufacturing capabilities
Sunrise Remedies formulates and manufactures pharmaceutical products in the form of tablets, capsules, oral liquids, and dry powders.
The company also produces a variety of other products for conditions such as erectile dysfunction, hepatitis, diabetes, and cardiac problems, as well as general products, and Ayurvedic, skin, and hair care products.
Sunrise Remedies was established in 1996 and exports its products to various international markets.
Summary
Ziovir-TLD represents a significant advancement in HIV treatment, combining Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate to effectively suppress viral replication and enhance immune function, thereby reducing the risk of complications and progression to AIDS. Manufactured by Sunrise Remedies, this fixed-dose combination exemplifies the ongoing commitment to improving health outcomes for individuals living with HIV.
